COVID-19 SARS-CoV-2 preprints from medRxiv and bioRxiv

31,244 Articles (22,733 medRxiv, 8,511 bioRxiv)

Most recent first Previous |  Page 848: Articles 8471-8480  | Next

Identification of C270 as a novel site for allosteric modulators of SARS-CoV-2 papain-like protease
Hu, H., Wang, Q., Su, H., Shao, Q., Zhao, W., Chen, G., Li, M., Xu, Y.
10.1101/2022.03.30.486313 — Posted: 2022-03-31
Methylene blue, Mycophenolic acid, Posaconazole, and Niclosamide inhibit SARS-CoV-2Omicron variant BA.1 infection of human airway epithelial explant cultures
Volle, R., Murer, L., Petkidis, A., Andriasyan, V., Savi, A., Bircher, C., Meili, N., Fisher, L., Sequeira, D. P., Mark, D. K., Gonzalez, A. G., Greber, U. F.
10.1101/2022.03.30.486461 — Posted: 2022-03-31
Brequinar and Dipyridamole in Combination Exhibits Synergistic Antiviral Activity Against SARS-CoV-2 in vitro: Rationale for a host-acting antiviral treatment strategy for COVID-19
Demarest, J. F., Kienle, M., Boytz, R., Ayres, M., Kim, E., Chung, D., Gandhi, V., Davey, R. A., Sykes, D. B., Shohdy, N., Pottage, J. C., Kumar, V. S.
10.1101/2022.03.30.486499 — Posted: 2022-03-31
Cross neutralization of Omicron BA.1 against BA.2 and BA.3 SARS-CoV-2
Zou, J., Kurhade, C., Xia, H., Liu, M., Xie, X., Ren, P., Shi, P.-Y.
10.1101/2022.03.30.486409 — Posted: 2022-03-31
Contributions of the N-terminal intrinsically disordered region of the SARS-CoV-2 nucleocapsid protein to RNA-induced phase separation
Zachrdla, M., Savastano, A., Ibanez de Opakua, A., Cima-Omori, M.-S., Zweckstetter, M.
10.1101/2022.03.30.486418 — Posted: 2022-03-31
Ancestral origins are associated with SARS-CoV-2 susceptibility and protection in a Florida patient population
Shen, Y., Khatri, B., Rananaware, S., Li, D., Ostrov, D., Jain, P., Lessard, C., Nguyen, C.
10.1101/2022.03.30.486345 — Posted: 2022-03-31
Emerging Therapies for COVID-19: the value of information from more clinical trials
Dijk, S. W., Krijkamp, E. M., Kunst, N., Gross, C. P., Wong, J. B., Hunink, M. G. M.
10.1101/2022.03.29.22273041 — Posted: 2022-03-30
SARS-CoV-2 spike-binding antibody longevity and protection from re-infection with antigenically similar SARS-CoV-2 variants
Kubale, J., Gleason, C. R., Carreno, J. M., Srivastava, K., PARIS Study Team, , Gordon, A., Krammer, F., Simon, V.
10.1101/2022.03.28.22273068 — Posted: 2022-03-30
Persistent health issues, adverse events of significant concern, and effectiveness of COVID-19 vaccination- findings from a real-world cohort study of healthcare workers in north India
Kaur, U., Bala, S., Joshi, A., Reddy, N. T. S., Japur, C., Chauhan, M., Pedapanga, N., Kumar, S., Mukherjee, A., Mishra, V., Talda, D., Singh, R., Gupta, R. K., Yadav, A. K., Rana, P. J., Srivastava, J., Bhat K, S., Singh, A., PG, N. K., Pandey, M., Patwardhan, K., Kansal, S., Chakrabarti, S. S.
10.1101/2022.03.26.22272613 — Posted: 2022-03-30
Adherence to and enforcement of non-pharmaceutical interventions (NPIs) for COVID-19 prevention in Nigeria, Rwanda, and Zambia: A mixed-methods analysis
Solomon, H., Thea, D. M., Galea, S., Sabin, L. L., Lucey, D. R., Hamer, D. H.
10.1101/2022.03.29.22273120 — Posted: 2022-03-30

RSS  Collection RSS | JSON

The feeds linked above output metadata for the 100 most recent papers in the collection.To access the metadata for the entire collection in JSON or XML, visit the collection API.

Subject Areas
* The Clinical Trials and Epidemiology subject categories are now closed to new submissions following the completion of bioRxiv's clinical research pilot project and launch of the dedicated health sciences server medRxiv (submit.medrxiv.org). New papers that report results of Clinical Trials must now be submitted to medRxiv. Most new Epidemiology papers also should be submitted to medRxiv, but if a paper contains no health-related information, authors may choose to submit it to another bioRxiv subject category (e.g., Genetics or Microbiology).